https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-01 / Ann. Oncol. 2018 May;29(5):1312-1319
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-01 / Ann. Oncol. 2018 May;29(5):1312-13192018-05-01 00:00:002019-02-15 08:39:10Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-01 / Vaccine 2018 05;36(23):3247-3253
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-01 / Vaccine 2018 05;36(23):3247-32532018-05-01 00:00:002019-02-15 08:45:20Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-26 / Front Oncol 2018;8:127
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-26 / Front Oncol 2018;8:1272018-04-26 00:00:002019-02-15 08:34:53Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-20 / Oncol Res Treat 2018;41(5):292-297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-20 / Oncol Res Treat 2018;41(5):292-2972018-04-20 00:00:002020-12-07 09:37:23Immunotherapy of Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-11 / Sci Transl Med 2018 Apr;10(436)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-11 / Sci Transl Med 2018 Apr;10(436)2018-04-11 00:00:002019-02-15 08:52:24Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-05 / PLoS ONE 2018;13(4):e0195425
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-05 / PLoS ONE 2018;13(4):e01954252018-04-05 00:00:002019-02-15 09:23:16Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-04 / Acta Trop. 2018 Jul;183:126-133
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-04 / Acta Trop. 2018 Jul;183:126-1332018-04-04 00:00:002019-02-15 09:23:15Newcastle disease virus strain AF2240 as an oncolytic virus: A review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-2225
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-22252018-04-01 00:00:002019-02-15 08:52:40WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-01 / JAMA Oncol 2018 Apr;4(4):483-492
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-01 / JAMA Oncol 2018 Apr;4(4):483-4922018-04-01 00:00:002019-02-15 09:37:56Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-170272018-03-30 00:00:002019-02-15 08:49:53Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
